Literature DB >> 16957567

Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.

Eiichiro Yamamoto1, Zhong-Fang Lai, Takuro Yamashita, Tomoko Tanaka, Keiichiro Kataoka, Yoshiko Tokutomi, Takaaki Ito, Hisao Ogawa, Shokei Kim-Mitsuyama.   

Abstract

OBJECTIVE: To examine the mechanism and significance of tachycardia-induced cardiac damage, using azelnidipine, a relatively new dihydropyridine calcium channel blocker which does not increase heart rate.
METHODS: Comparing azelnidipine and amlodipine, we examined the cardiac effects and the direct effects on a sinus node/atrial preparation in stroke-prone spontaneously hypertensive rats (spSHRs). By pacing the right atrium, we examined the effect of tachycardia per se on cardiac oxidative stress. Using apocynin, a reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor, we investigated the role of oxidative stress in cardiac remodelling.
RESULTS: Azelnidipine suppressed cardiac hypertrophy, fibrosis, NADPH oxidase and superoxide in spSHRs more potently than amlodipine, and was associated with lower heart rates than amlodipine. Azelnidipine caused a greater reduction than amlodipine in the beat rate of the sinus node/atrial preparation of spSHRs. A 10 or 20% increase in heart rate, independent of blood pressure or sympathetic nerve activity, significantly enhanced cardiac NADPH oxidase activity, superoxide and activated mitogen-activated protein kinases. Reduction of cardiac oxidative stress by apocynin led to the suppression of cardiac hypertrophy, inflammation and fibrosis in spSHRs, beyond its hypotensive effect.
CONCLUSIONS: Our work provided evidence that the increase in heart rate per se, independent of sympathetic nerve activity, enhances cardiac oxidative stress and activates mitogen-activated protein kinases, which seem to be responsible for cardiac remodelling. Azelnidipine, without causing an increase in heart rate, has the potential to be useful for the treatment of cardiac remodelling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957567     DOI: 10.1097/01.hjh.0000244956.47114.c1

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

2.  Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats.

Authors:  Takao Nishizawa; Xian Wu Cheng; Zhehu Jin; Koji Obata; Kohzo Nagata; Akihiro Hirashiki; Takeshi Sasaki; Akiko Noda; Kyosuke Takeshita; Hideo Izawa; Guo-Ping Shi; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

3.  Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.

Authors:  Y F Dong; L Liu; K Kataoka; T Nakamura; M Fukuda; Y Tokutomi; H Nako; H Ogawa; S Kim-Mitsuyama
Journal:  Diabetologia       Date:  2009-11-06       Impact factor: 10.122

4.  Bone morphogenetic protein-4 induces upregulation of Cav3.1 Ca²⁺ channels in HL-1 atrial myocytes.

Authors:  Chao-Wei Hu; Qi Li; Ying Zhang; Yu-Hong Li; Hong-Chao Jiang; Ming-Yu Liu; Shan-Liang Li; Wei Han; De-Li Dong
Journal:  Pflugers Arch       Date:  2014-02-08       Impact factor: 3.657

5.  Short-term effects of electrically induced tachycardia on antioxidant defenses in the normal and hypertrophied rat left ventricle.

Authors:  Barbara Kłapcińska; Ewa Sadowska-Krepa; Sławomir Jagsz; Andrzej Sobczak; Małgorzata Zendzian-Piotrowska; Jan Górski; Józef Langfort
Journal:  J Physiol Sci       Date:  2009-02-26       Impact factor: 2.781

6.  Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

Authors:  Takeshi Takami; Yoshihiko Saito
Journal:  Vasc Health Risk Manag       Date:  2011-06-17

7.  Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.

Authors:  Bowen Lin; Nobutaka Koibuchi; Yu Hasegawa; Daisuke Sueta; Kensuke Toyama; Ken Uekawa; MingJie Ma; Takashi Nakagawa; Hiroaki Kusaka; Shokei Kim-Mitsuyama
Journal:  Cardiovasc Diabetol       Date:  2014-10-26       Impact factor: 9.951

8.  DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.

Authors:  Nobutaka Koibuchi; Yu Hasegawa; Tetsuji Katayama; Kensuke Toyama; Ken Uekawa; Daisuke Sueta; Hiroaki Kusaka; MingJie Ma; Takashi Nakagawa; Bowen Lin; Shokei Kim-Mitsuyama
Journal:  Cardiovasc Diabetol       Date:  2014-11-29       Impact factor: 9.951

9.  High-Fat-Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer's Disease, Independently of Metabolic Disorders.

Authors:  Bowen Lin; Yu Hasegawa; Koki Takane; Nobutaka Koibuchi; Cheng Cao; Shokei Kim-Mitsuyama
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

10.  Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial.

Authors:  Takeshi Takami; Yoshihiko Saito
Journal:  Drug Des Devel Ther       Date:  2013-03-22       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.